Implications of mitochondrial DNA mutations and mitochondrial dysfunction in tumorigenesis

Cell Research

Volumn 19, Issue 7, 2009, Pages 802-815

  Lu, Jianxin ^a   Sharma, Lokendra Kumar ^b   Bai, Yidong ^a,b  

^a WENZHOU MEDICAL UNIVERSITY   (China)

^b Mays Cancer Center at UT Health San Antonio   (United States)

Author keywords

Apoptosis; Cancer; Mitochondrial DNA mutation; ROS

Indexed keywords

MITOCHONDRIAL DNA; REACTIVE OXYGEN METABOLITE;

ARTICLE; CHEMISTRY; GENETICS; GENOMIC INSTABILITY; METABOLISM; MITOCHONDRION; MUTATION; NEOPLASM; OXIDATIVE PHOSPHORYLATION; SIGNAL TRANSDUCTION;

DNA, MITOCHONDRIAL; GENOMIC INSTABILITY; MITOCHONDRIA; MUTATION; NEOPLASMS; OXIDATIVE PHOSPHORYLATION; REACTIVE OXYGEN SPECIES; SIGNAL TRANSDUCTION;

EID: 68149137896     PISSN: 10010602     EISSN: 17487838     Source Type: Journal    
DOI: 10.1038/cr.2009.69     Document Type: Article

References (203)

1. Attardi G, Schatz G. Biogenesis of mitochondria. Annu Rev Cell Biol 1988; 4:289-333.
2. Wang X. The expanding role of mitochondria in apoptosis. Genes Dev 2001; 15:2922-2933.
3. Kroemer G, Reed JC. Mitochondrial control of cell death. Nat Med 2000; 6:513-519.
4. Rustin P. Mitochondria, from cell death to proliferation. Nat Genet 2002; 30:352-353.
5. Rizzuto R, Bernardi P, Pozzan T. Mitochondria as all-round players of the calcium game. J Physiol 2000; 529 Pt 1:37-47.
6. 2+ signaling. Curr Opin Neurobiol 1998; 8:398-404.
7. Wallace DC. Mitochondrial DNA in aging and disease. Sci Am 1997; 277:40-47.
8. DiMauro S, Schon EA. Mitochondrial DNA mutations in human disease. Am J Med Genet 2001; 106:18-26.
9. DiMauro S. Mitochondrial DNA medicine. Biosci Rep 2007; 27:5-9.
10. Reeve AK, Krishnan KJ, Turnbull D. Mitochondrial DNA mutations in disease, aging, and neurodegeneration. Ann N Y Acad Sci 2008; 1147:21-29.
11. Wallace DC. A mitochondrial paradigm for degenerative diseases and ageing. Novartis Found Symp 2001; 235:247-263; discussion 263-246.
12. Polyak K, Li Y, Zhu H, et al. Somatic mutations of the mitochondrial genome in human colorectal tumours. Nat Genet 1998; 20:291-293.
13. Penta JS, Johnson FM, Wachsman JT, Copeland WC. Mitochondrial DNA in human malignancy. Mutat Res 2001; 488:119-133.
14. Hochhauser D. Relevance of mitochondrial DNA in cancer. Lancet 2000; 356:181-182.
15. Anderson S, Bankier AT, Barrell BG, et al. Sequence and organization of the human mitochondrial genome. Nature 1981; 290:457-465.
16. Attardi G. Animal mitochondrial DNA: an extreme example of genetic economy. Int Rev Cytol 1985; 93:93-145.
17. Warburg O. On the origin of cancer cell. Science 1956; 123:309-314.
18. Pedersen PL. Tumor mitochondria and the bioenergetics of cancer cells. Prog Exp Tumor Res 1978; 22:190-274.
19. Bando H, Atsumi T, Nishio T, et al. Phosphorylation of the 6-phosphofructo-2-kinase/fructose 2,6-bisphosphatase/ PFKFB3 family of glycolytic regulators in human cancer. Clin Cancer Res 2005; 11:5784-5792.
20. Chowdhury SK, Gemin A, Singh G. High activity of mitochondrial glycerophosphate dehydrogenase and glycerophos-phate-dependent ROS production in prostate cancer cell lines. Biochem Biophys Res Commun 2005; 333:1139-1145.
21. Cuezva JM, Krajewska M, de Heredia ML, et al. The bioenergetic signature of cancer: a marker of tumor progression. Cancer Res 2002; 62:6674-6681.
22. Arnould T, Vankoningsloo S, Renard P, et al. CREB activation induced by mitochondrial dysfunction is a new signaling pathway that impairs cell proliferation. EMBO J 2002; 21:53-63.
23. Pelicano H, Xu RH, Du M, et al. Mitochondrial respiration defects in cancer cells cause activation of Akt survival pathway through a redox-mediated mechanism. J Cell Biol 2006; 175:913-923.
24. Gottlob K, Majewski N, Kennedy S, et al. Inhibition of early apoptotic events by Akt/PKB is dependent on the frst committed step of glycolysis and mitochondrial hexokinase. Genes Dev 2001; 15:1406-1418.
25. Plas DR, Thompson CB. Akt-dependent transformation: there is more to growth than just surviving. Oncogene 2005; 24:7435-7442.
26. Elstrom RL, Bauer DE, Buzzai M, et al. Akt stimulates aerobic glycolysis in cancer cells. Cancer Res 2004; 64:3892-3899.
27. Lopez-Rios F, Sanchez-Arago M, Garcia-Garcia E, et al. Loss of the mitochondrial bioenergetic capacity underlies the glucose avidity of carcinomas. Cancer Res 2007; 67:9013-9017.
28. Wu M, Neilson A, Swift AL, et al. Multiparameter metabolic analysis reveals a close link between attenuated mitochon-drial bioenergetic function and enhanced glycolysis dependency in human tumor cells. Am J Physiol Cell Physiol 2007; 292:C125-C136.
29. Wang GL, Semenza GL. General involvement of hypoxia-inducible factor 1 in transcriptional response to hypoxia. Proc Natl Acad Sci USA 1993; 90:4304-4308.
30. Clayton DA, Vinograd J. Circular dimer and catenate forms of mitochondrial DNA in human leukaemic leucocytes. J Pers 1967; 35:652-657.
31. Clayton DA, Vinograd J. Complex mitochondrial DNA in leukemic and normal human myeloid cells. Proc Natl Acad Sci USA 1969; 62:1077-1084.
32. Brandon M, Baldi P, Wallace DC. Mitochondrial mutations in cancer. Oncogene 2006; 25:4647-4662.
33. Chatterjee A, Mambo E, Sidransky D. Mitochondrial DNA mutations in human cancer. Oncogene 2006; 25:4663-4674.
34. Liu VW, Shi HH, Cheung AN, et al. High incidence of somatic mitochondrial DNA mutations in human ovarian carcinomas. Cancer Res 2001; 61:5998-6001.
35. Nomoto S, Yamashita K, Koshikawa K, Nakao A, Sidransky D. Mitochondrial D-loop mutations as clonal markers in multicentric hepatocellular carcinoma and plasma. Clin Cancer Res 2002; 8:481-487.
36. Zhao YB, Yang HY, Zhang XW, Chen G Y. Mutation in Dloop region of mitochondrial DNA in gastric cancer and its signifcance. World J Gastroenterol 2005; 11:3304-3306.
37. Mambo E, Gao X, Cohen Y, et al. Electrophile and oxidant damage of mitochondrial DNA leading to rapid evolution of homoplasmic mutations. Proc Natl Acad Sci USA 2003; 100:1838-1843.
38. Gasparre G, Hervouet E, de Laplanche E, et al. Clonal expansion of mutated mitochondrial DNA is associated with tumor formation and complex I defciency in the benign renal onco-cytoma. Hum Mol Genet 2008; 17:986-995.
39. Kamalidehghan B, Houshmand M, Ismail P, Panahi MS, Akbari Mh. Delta mtDNA4977 is more common in non-tumoral cells from gastric cancer sample. Arch Med Res 2006; 37:730-735.
40. Dai JG, Xiao YB, Min JX, et al. Mitochondrial DNA 4977 BP deletion mutations in lung carcinoma. Indian J Cancer 2006; 43:20-25.
41. Yin PH, Lee HC, Chau GY, et al. Alteration of the copy number and deletion of mitochondrial DNA in human hepatocel-lular carcinoma. Br J Cancer 2004; 90:2390-2396.
42. King MP, Attardi G. Human cells lacking mtDNA: repopulation with exogenous mitochondria by complementation. Science 1989; 246:500-503.
43. Shidara Y, Yamagata K, Kanamori T, et al. Positive contribution of pathogenic mutations in the mitochondrial genome to the promotion of cancer by prevention from apoptosis. Cancer Res 2005; 65:1655-1663.
44. Petros JA, Baumann AK, Ruiz-Pesini E, et al. mtDNA mutations increase tumorigenicity in prostate cancer. Proc Natl Acad Sci USA 2005; 102:719-724.
45. Arnold RS, Sun CQ, Richards JC, et al. Mitochondrial DNA mutation stimulates prostate cancer growth in bone stromal environment. Prostate 2009; 69:1-11.
46. Ishikawa K, Takenaga K, Akimoto M, et al. ROS-generating mitochondrial DNA mutations can regulate tumor cell metastasis. Science 2008; 320:661-664.
47. Park JS, Sharma LK, Li HZ, et al. A heteroplasmic, not homoplasmic, mitochondrial DNA mutation promotes tumorigenesis via alteration in reactive oxygen species generation and apoptosis. Hum Mol Genet 2009; 18:1578-1589.
48. Chance B, Sies H, Boveris A. Hydroperoxide metabolism in mammalian organs. Physiol Rev 1979; 59:527-605.
49. Ames BN, Shigenaga MK. Oxidants are a major contributor to aging. Ann N Y Acad Sci 1992; 663:85-96.
50. Harman D. Free radicals in aging. Mol Cell Biochem 1988; 84:155-161.
51. Gamaley IA, Klyubin IV. Roles of reactive oxygen species: signaling and regulation of cellular functions. Int Rev Cytol 1999; 188:203-255.
52. Finkel T. Reactive oxygen species and signal transduction. IUBMB Life 2001; 52:3-6.
53. Lander HM. An essential role for free radicals and derived species in signal transduction. FASEB J 1997; 11:118-124.
54. Burdon RH. Superoxide and hydrogen peroxide in relation to mammalian cell proliferation. Free Radic Biol Med 1995; 18:775-794.
55. Pagano G. Redox-modulated xenobiotic action and ROS formation: a mirror or a window? Hum Exp Toxicol 2002; 21:77-81.
56. Preston TJ, Muller WJ, Singh G. Scavenging of extracellular H2O2 by catalase inhibits the proliferation of HER-2/Neutransformed rat-1 fbroblasts through the induction of a stress response. J Biol Chem 2001; 276:9558-9564.
57. Zhao ZQ. Oxidative stress-elicited myocardial apoptosis during reperfusion. Curr Opin Pharmacol 2004; 4:159-165.
58. Kamata H, Hirata H. Redox regulation of cellular signalling. Cell Signal 1999; 11:1-14.
59. Sundaresan M, Yu ZX, Ferrans VJ, Irani K, Finkel T. Requirement for generation of H2O2 for platelet-derived growth factor signal transduction. Science 1995; 270:296-299.
60. Guyton KZ, Liu Y, Gorospe M, Xu Q, Holbrook NJ. Activation of mitogen-activated protein kinase by H2O2. Role in cell survival following oxidant injury. J Biol Chem 1996; 271:4138-4142.
61. Rao GN. Hydrogen peroxide induces complex formation of SHC-Grb2-SOS with receptor tyrosine kinase and activates Ras and extracellular signal-regulated protein kinases group of mitogen-activated protein kinases. Oncogene 1996; 13:713-719.
62. Mercurio F, Manning AM. NF-kappaB as a primary regulator of the stress response. Oncogene 1999; 18:6163-6171.
63. Adler V, Yin Z, Fuchs SY, et al. Regulation of JNK signaling by GSTp. EMBO J 1999; 18:1321-1334.
64. Preston TJ, Abadi A, Wilson L, Singh G. Mitochondrial contributions to cancer cell physiology: potential for drug development. Adv Drug Deliv Rev 2001; 49:45-61.
65. Hampton MB, Kettle AJ, Winterbourn CC. Inside the neu-trophil phagosome: oxidants, myeloperoxidase, and bacterial killing. Blood 1998; 92:3007-3017.
66. Amstad PA, Krupitza G, Cerutti PA. Mechanism of c-fos induction by active oxygen. Cancer Res 1992; 52:3952-3960.
67. Nose K, Ohba M. Functional activation of the Egr-1 (early growth response-1) gene by hydrogen peroxide. Biochem J 1996; 316 (Pt 2):381-383.
68. Nose K, Shibanuma M, Kikuchi K, et al. Transcriptional activation of early-response genes by hydrogen peroxide in a mouse osteoblastic cell line. Eur J Biochem 1991; 201:99-106.
69. Ha HC, Thiagalingam A, Nelkin BD, Casero RA Jr. Reactive oxygen species are critical for the growth and differentiation of medullary thyroid carcinoma cells. Clin Cancer Res 2000; 6:3783-3787.
70. Sundaresan M, Yu ZX, Ferrans VJ, et al. Regulation of reactive-oxygen-species generation in fibroblasts by Rac1. Biochem J 1996; 318 (Pt 2):379-382.
71. Semenza GL. O2-regulated gene expression: transcriptional control of cardiorespiratory physiology by HIF-1. J Appl Physiol 2004; 96:1173-1177; discussion 1170-1172.
72. Semenza GL. HIF-1, O(2), and the 3 PHDs: how animal cells signal hypoxia to the nucleus. Cell 2001; 107:1-3.
73. Zhang H, Gao P, Fukuda R, et al. HIF-1 inhibits mitochondri-al biogenesis and cellular respiration in VHL-defcient renal cell carcinoma by repression of C-MYC activity. Cancer Cell 2007; 11:407-420.
74. Lin JD. Minireview: the PGC-1 coactivator networks: chromatin-remodeling and mitochondrial energy metabolism. Mol Endocrinol 2009; 23:2-10.
75. Kim JW, Tchernyshyov I, Semenza GL, Dang CV. HIF-1-mediated expression of pyruvate dehydrogenase kinase: a metabolic switch required for cellular adaptation to hypoxia. Cell Metab 2006; 3:177-185.
76. Papandreou I, Cairns RA, Fontana L, Lim AL, Denko NC. HIF-1 mediates adaptation to hypoxia by actively downregu-lating mitochondrial oxygen consumption. Cell Metab 2006; 3:187-197.
77. Fukuda R, Zhang H, Kim JW, et al. HIF-1 regulates cyto-chrome oxidase subunits to optimize effciency of respiration in hypoxic cells. Cell 2007; 129:111-122.
78. Klimova T, Chandel NS. Mitochondrial complex III regulates hypoxic activation of HIF. Cell Death Differ 2008; 15:660-666.
79. Zhou S, Kachhap S, Sun W, et al. Frequency and phenotypic implications of mitochondrial DNA mutations in human squamous cell cancers of the head and neck. Proc Natl Acad Sci USA 2007; 104:7540-7545.
80. Kroemer G. Mitochondrial control of apoptosis: an overview. Biochem Soc Symp 1999; 66:1-15.
81. Johnstone RW, Ruefi AA, Lowe SW. Apoptosis: a link between cancer genetics and chemotherapy. Cell 2002; 108:153-164.
82. Liu X, Kim CN, Yang J, Jemmerson R, Wang X. Induction of apoptotic program in cell-free extracts: requirement for dATP and cytochrome c. Cell 1996; 862:147-157.
83. Kwong JQ, Henning MS, Starkov AA, Manfredi G. The mitochondrial respiratory chain is a modulator of apoptosis. J Cell Biol 2007; 179:1163-1177.
84. Raha S, Robinson BH. Mitochondria, oxygen free radicals, and apoptosis. Am J Med Genet 2001; 106:62-70.
85. Shen YH, Wang XL, Wilcken DE. Nitric oxide induces and inhibits apoptosis through different pathways. FEBS Lett 1998; 433:125-131.
86. Ghosh JC, Dohi T, Kang BH, Altieri DC. Hsp60 regulation of tumor cell apoptosis. J Biol Chem 2008; 283:5188-5194.
87. Kang BH, Plescia J, Dohi T, et al. Regulation of tumor cell mitochondrial homeostasis by an organelle-specific Hsp90 chaperone network. Cell 2007; 131:257-270.
88. Butow RA, Avadhani NG. Mitochondrial signaling: the retrograde response. Mol Cell 2004; 14:1-15.
89. Wang H, Morais R. Up-regulation of nuclear genes in response to inhibition of mitochondrial DNA expression in chicken cells. Biochim Biophys Acta 1997; 1352:325-334.
90. Marusich MF, Robinson BH, Taanman JW, et al. Expression of mtDNA and nDNA encoded respiratory chain proteins in chemically and genetically-derived Rho0 human fbroblasts: a comparison of subunit proteins in normal fbroblasts treated with ethidium bromide and fibroblasts from a patient with mtDNA depletion syndrome. Biochim Biophys Acta 1997; 1362:145-159.
91. Freyssenet D, Irrcher I, Connor MK, Di Carlo M, Hood DA. Calcium-regulated changes in mitochondrial phenotype in skeletal muscle cells. Am J Physiol Cell Physiol 2004; 286:C1053-1061.
92. Woo DK, Phang TL, Trawick JD, Poyton RO. Multiple pathways of mitochondrial-nuclear communication in yeast: Intergenomic signaling involves ABF1 and affects a different set of genes than retrograde regulation. Biochim Biophys Acta 2009; 1789:135-145.
93. Owusu-Ansah E, Yavari A, Mandal S, Banerjee U. Distinct mitochondrial retrograde signals control the G1-S cell cycle checkpoint. Nat Genet 2008; 40:356-361.
94. Selak MA, Armour SM, MacKenzie ED, et al. Succinate links TCA cycle dysfunction to oncogenesis by inhibiting HIF-alpha prolyl hydroxylase. Cancer Cell 2005; 7:77-85.
95. Howell AN, Sager R. Tumorigenicity and its suppression in cybrids of mouse and Chinese hamster cell lines. Proc Natl Acad Sci USA 1978; 75:2358-2362.
96. Biswas G, Adebanjo OA, Freedman BD, et al. Retrograde Ca2+ signaling in C2C12 skeletal myocytes in response to mitochondrial genetic and metabolic stress: a novel mode of inter-organelle crosstalk. EMBO J 1999; 18:522-533.
97. Amuthan G, Biswas G, Ananadatheerthavarada HK, et al. Mitochondrial stress-induced calcium signaling, phenotypic changes and invasive behavior in human lung carcinoma A549 cells. Oncogene 2002; 21:7839-7849.
98. Amuthan G, Biswas G, Zhang SY, et al. Mitochondria-to-nucleus stress signaling induces phenotypic changes, tumor progression and cell invasion. EMBO J 2001; 20:1910-1920.
99. Biswas G, Guha M, Avadhani NG. Mitochondria-to-nucleus stress signaling in mammalian cells: nature of nuclear gene targets, transcription regulation, and induced resistance to apoptosis. Gene 2005; 354:132-139.
100. Guha M, Srinivasan S, Biswas G, Avadhani NG. Activation of a novel calcineurin-mediated insulin-like growth factor-1 receptor pathway, altered metabolism, and tumor cell invasion in cells subjected to mitochondrial respiratory stress. J Biol Chem 2007; 282:14536-14546.
101. Biswas G, Srinivasan S, Anandatheerthavarada HK, Avadhani NG. Dioxin-mediated tumor progression through activation of mitochondria-to-nucleus stress signaling. Proc Natl Acad Sci USA 2008; 105:186-191.
102. Kulawiec M, Arnouk H, Desouki MM, et al. Proteomic analysis of mitochondria-to-nucleus retrograde response in human cancer. Cancer Biol Ther 2006; 5:967-975.
103. Park SY, Lee S, Park KS, Lee HK, Lee W. Proteomic analysis of cellular change involved in mitochondria-to-nucleus communication in L6 GLUT4myc myocytes. Proteomics 2006; 6:1210-1222.
104. Loffler M, Jockel J, Schuster G, Becker C. Dihydroorotat-ubiquinone oxidoreductase links mitochondria in the biosynthesis of pyrimidine nucleotides. Mol Cell Biochem 1997; 174:125-129.
105. Traut TW. Physiological concentrations of purines and py-rimidines. Mol Cell Biochem 1994; 140:1-22.
106. Rasmussen AK, Chatterjee A, Rasmussen LJ, Singh KK. Mitochondria-mediated nuclear mutator phenotype in Saccha-romyces cerevisiae. Nucleic Acids Res 2003; 31:3909-3917.
107. Desler C, Munch-Petersen B, Stevnsner T, et al. Mitochondria as determinant of nucleotide pools and chromosomal stability. Mutat Res 2007; 625:112-124.
108. Meuth M. The molecular basis of mutations induced by deoxyribonucleoside triphosphate pool imbalances in mammalian cells. Exp Cell Res 1989; 181:305-316.
109. Liu L, Trimarchi JR, Smith PJ, Keefe DL. Mitochondrial dysfunction leads to telomere attrition and genomic instability. Aging Cell 2002; 1:40-46.
110. Salas A, Yao YG, Macaulay V, et al. A critical reassessment of the role of mitochondria in tumorigenesis. PLoS Med 2005; 2:e296.
111. Fang H, Lu J, Wei J, et al. Mitochondrial DNA mutations in the D-loop region may not be frequent in cervical cancer: a discussion on pitfalls in mitochondrial DNA studies. J Cancer Res Clin Oncol 2009.
112. He L, Luo L, Proctor SJ, et al. Somatic mitochondrial DNA mutations in adult-onset leukaemia. Leukemia 2003; 17:2487-2491.
113. Carew JS, Zhou Y, Albitar M, et al. Mitochondrial DNA mutations in primary leukemia cells after chemotherapy: clinical significance and therapeutic implications. Leukemia 2003; 17:1437-1447.
114. Linnartz B, Anglmayer R, Zanssen S. Comprehensive scanning of somatic mitochondrial DNA alterations in acute leukemia developing from myelodysplastic syndromes. Cancer Res 2004; 64:1966-1971.
115. Habano W, Sugai T, Yoshida T, Nakamura S. Mitochondrial gene mutation, but not large-scale deletion, is a feature of colorectal carcinomas with mitochondrial microsatellite instability. Int J Cancer 1999; 83:625-629.
116. Nishikawa M, Oshitani N, Matsumoto T, et al. Accumulation of mitochondrial DNA mutation with colorectal carcinogen-esis in ulcerative colitis. Br J Cancer 2005; 93:331-337.
117. Allalunis-Turner J, Ma I, Hanson J, Pearcey RG. mtDNA mutations in invasive cervix tumors: a retrospective analysis. Cancer Lett 2006; 243:193-201.
118. Jin X, Zhang J, Gao Y, et al. Relationship between mitochon-drial DNA mutations and clinical characteristics in human lung cancer. Mitochondrion 2007; 7:347-353.
119. Durham SE, Krishnan KJ, Betts J, Birch-Machin MA. Mitochondrial DNA damage in non-melanoma skin cancer. Br J Cancer 2003; 88:90-95.
120. Girald-Rosa W, Vleugels RA, Musiek AC, Sligh JE. High-throughput mitochondrial genome screening method for non-melanoma skin cancer using multiplexed temperature gradient capillary electrophoresis. Clin Chem 2005; 51:305-311.
121. Costa-Guda J, Tokura T, Roth SI, Arnold A. Mitochondrial DNA mutations in oxyphilic and chief cell parathyroid adenomas. BMC Endocr Disord 2007; 7:8.
122. Yeh JJ, Lunetta KL, van Orsouw NJ, et al. Somatic mitochon-drial DNA (mtDNA) mutations in papillary thyroid carcinomas and differential mtDNA sequence variants in cases with thyroid tumours. Oncogene 2000; 19:2060-2066.
123. Gasparre G, Porcelli AM, Bonora E, et al. Disruptive mitochondrial DNA mutations in complex I subunits are markers of oncocytic phenotype in thyroid tumors. Proc Natl Acad Sci USA 2007; 104:9001-9006.
124. Abu-Amero KK, Alzahrani AS, Zou M, Shi Y. Association of mitochondrial DNA transversion mutations with familial medullary thyroid carcinoma/multiple endocrine neoplasia type 2 syndrome. Oncogene 2006; 25:677-684.
125. Bonora E, Porcelli AM, Gasparre G, et al. Defective oxidative phosphorylation in thyroid oncocytic carcinoma is associated with pathogenic mitochondrial DNA mutations affecting complexes I and III. Cancer Res 2006; 66:6087-6096.
126. Maximo V, Soares P, Lima J, Cameselle-Teijeiro J, Sobrinho-Simoes M. Mitochondrial DNA somatic mutations (point mutations and large deletions) and mitochondrial DNA variants in human thyroid pathology: a study with emphasis on Hurthle cell tumors. Am J Pathol 2002; 160:1857-1865.
127. Rogounovitch T, Saenko V, Yamashita S. Mitochondrial DNA and human thyroid diseases. Endocr J 2004; 51:265-277.
128. Mayr JA, Meierhofer D, Zimmermann F, et al. Loss of complex I due to mitochondrial DNA mutations in renal oncocy-toma. Clin Cancer Res 2008; 14:2270-2275.
129. Mithani SK, Taube JM, Zhou S, et al. Mitochondrial mutations are a late event in the progression of head and neck squamous cell cancer. Clin Cancer Res 2007; 13:4331-4335.
130. Sui G, Zhou S, Wang J, et al. Mitochondrial DNA mutations in preneoplastic lesions of the gastrointestinal tract: a biomarker for the early detection of cancer. Mol Cancer 2006; 5:73.
131. Jeronimo C, Nomoto S, Caballero OL, et al. Mitochondrial mutations in early stage prostate cancer and bodily fuids. Oncogene 2001; 20:5195-5198.
132. Parrella P, Xiao Y, Fliss M, et al. Detection of mitochondrial DNA mutations in primary breast cancer and fne-needle aspirates. Cancer Res 2001; 61:7623-7626.
133. Maximo V, Soares P, Seruca R, et al. Microsatellite instability, mitochondrial DNA large deletions, and mitochondrial DNA mutations in gastric carcinoma. Genes Chromosomes Cancer 2001; 32:136-143.
134. Gallardo ME, Moreno-Loshuertos R, Lopez C, et al. m.6267G>A: a recurrent mutation in the human mitochon-drial DNA that reduces cytochrome c oxidase activity and is associated with tumors. Hum Mutat 2006; 27:575-582.
135. Tan DJ, Bai RK, Wong LJ. Comprehensive scanning of somatic mitochondrial DNA mutations in breast cancer. Cancer Res 2002; 62:972-976.
136. Wong LJ, Lueth M, Li XN, Lau CC, Vogel H. Detection of mitochondrial DNA mutations in the tumor and cerebrospinal fuid of medulloblastoma patients. Cancer Res 2003; 63:3866-3871.
137. Prior SL, Griffths AP, Baxter JM, et al. Mitochondrial DNA mutations in oral squamous cell carcinoma. Carcinogenesis 2006; 27:945-950.
138. Tan DJ, Chang J, Chen WL, et al. Somatic mitochondrial DNA mutations in oral cancer of betel quid chewers. Ann N Y Acad Sci 2004; 1011:310-316.
139. Tan DJ, Chang J, Chen WL, et al. Novel heteroplasmic frame-shift and missense somatic mitochondrial DNA mutations in oral cancer of betel quid chewers. Genes Chromosomes Cancer 2003; 37:186-194.
140. Nagy A, Wilhelm M, Kovacs G. Mutations of mtDNA in renal cell tumours arising in end-stage renal disease. J Pathol 2003; 199:237-242.
141. Abu-Amero KK, Alzahrani AS, Zou M, Shi Y. High frequency of somatic mitochondrial DNA mutations in human thyroid carcinomas and complex I respiratory defect in thyroid cancer cell lines. Oncogene 2005; 24:1455-1460.
142. Hibi K, Nakayama H, Yamazaki T, et al. Mitochondrial DNA alteration in esophageal cancer. Int J Cancer 2001; 92:319-321.
143. Fliss MS, Usadel H, Caballero OL, et al. Facile detection of mitochondrial DNA mutations in tumors and bodily fluids. Science 2000; 287:2017-2019.
144. Nagy A, Wilhelm M, Sukosd F, Ljungberg B, Kovacs G. Somatic mitochondrial DNA mutations in human chromophobe renal cell carcinomas. Genes Chromosomes Cancer 2002; 35:256-260.
145. Tzen CY, Mau BL, Wu TY. ND4 mutation in transitional cell carcinoma: does mitochondrial mutation occur before tumori-genesis? Mitochondrion 2007; 7:273-278.
146. Kiebish MA, Seyfried TN. Absence of pathogenic mitochon-drial DNA mutations in mouse brain tumors. BMC Cancer 2005; 5:102.
147. Gomez-Zaera M, Abril J, Gonzalez L, et al. Identifcation of somatic and germline mitochondrial DNA sequence variants in prostate cancer patients. Mutat Res 2006; 595:42-51.
148. Habano W, Nakamura S, Sugai T. Microsatellite instability in the mitochondrial DNA of colorectal carcinomas: evidence for mismatch repair systems in mitochondrial genome. Oncogene 1998; 17:1931-1937.
149. Khrapko K, Nekhaeva E, Kraytsberg Y, Kunz W. Clonal expansions of mitochondrial genomes: implications for in vivo mutational spectra. Mutat Res 2003; 522:13-19.
150. Witte J, Lehmann S, Wulfert M, Yang Q, Roher HD. Mito-chondrial DNA mutations in differentiated thyroid cancer with respect to the age factor. World J Surg 2007; 31:51-59.
151. Tan DJ, Chang J, Liu LL, et al. Signifcance of somatic mutations and content alteration of mitochondrial DNA in esophageal cancer. BMC Cancer 2006; 6:93.
152. Habano W, Sugai T, Nakamura SI, et al. Microsatellite instability and mutation of mitochondrial and nuclear DNA in gastric carcinoma. Gastroenterology 2000; 118:835-841.
153. Chen JZ, Gokden N, Greene GF, Green B, Kadlubar FF. Simultaneous generation of multiple mitochondrial DNA mutations in human prostate tumors suggests mitochondrial hypermutagenesis. Carcinogenesis 2003; 24:1481-1487.
154. Pang LJ, Shao JY, Liang XM, Xia YF, Zeng YX. Mitochondrial DNA somatic mutations are frequent in nasopharyngeal carcinoma. Cancer Biol Ther 2008; 7:198-207.
155. Kirches E, Krause G, Warich-Kirches M, et al. High frequency of mitochondrial DNA mutations in glioblastoma multiforme identifed by direct sequence comparison to blood samples. Int J Cancer 2001; 93:534-538.
156. Lievre A, Chapusot C, Bouvier AM, et al. Clinical value of mitochondrial mutations in colorectal cancer. J Clin Oncol 2005; 23:3517-3525.
157. Wong LJ, Tan DJ, Bai RK, Yeh KT, Chang J. Molecular alterations in mitochondrial DNA of hepatocellular carcinomas: is there a correlation with clinicopathological profle? J Med Genet 2004; 41:e65.
158. Kim HS, Lim HS, Lee SH, et al. Mitochondrial microsatel-lite instability of colorectal cancer stroma. Int J Cancer 2006; 119:2607-2611.
159. Wang CY, Wang HW, Yao YG, Kong QP, Zhang YP. Somatic mutations of mitochondrial genome in early stage breast cancer. Int J Cancer 2007; 121:1253-1256.
160. Parrella P, Seripa D, Matera MG, et al. Mutations of the D310 mitochondrial mononucleotide repeat in primary tumors and cytological specimens. Cancer Lett 2003; 190:73-77.
161. Zhu W, Qin W, Bradley P, et al. Mitochondrial DNA mutations in breast cancer tissue and in matched nipple aspirate fuid. Carcinogenesis 2005; 26:145-152.
162. Tseng LM, Yin PH, Chi CW, et al. Mitochondrial DNA mutations and mitochondrial DNA depletion in breast cancer. Genes Chromosomes Cancer 2006; 45:629-638.
163. Yu M, Shi Y, Zhang F, et al. Sequence variations of mitochondrial DNA D-loop region are highly frequent events in familial breast cancer. J Biomed Sci 2008; 15:535-543.
164. Bertagnolli AC, Soares P, van Asch B, et al. An assessment of the clonality of the components of canine mixed mammary tumours by mitochondrial DNA analysis. Vet J 2008 Aug 25. doi:10.1016/j.tvjl.2008.07.005
165. Rosson D, Keshgegian AA. Frequent mutations in the mitochondrial control region DNA in breast tissue. Cancer Lett 2004; 215:89-94.
166. Chen D, Zhan H. Study on the mutations in the D-loop region of mitochondrial DNA in cervical carcinoma. J Cancer Res Clin Oncol 2008; 135:291-295.
167. Sharma H, Singh A, Sharma C, Jain SK, Singh N. Mutations in the mitochondrial DNA D-loop region are frequent in cervical cancer. Cancer Cell Int 2005; 5:34.
168. Legras A, Lievre A, Bonaiti-Pellie C, et al. Mitochondrial D310 mutations in colorectal adenomas: an early but not causative genetic event during colorectal carcinogenesis. Int J Cancer 2008; 122:2242- 2248.
169. Hibi K, Nakayama H, Yamazaki T, et al. Detection of mitochondrial DNA alterations in primary tumors and corresponding serum of colorectal cancer patients. Int J Cancer 2001; 94:429-431.
170. Guleng G, Lovig T, Meling GI, Andersen SN, Rognum TO. Mitochondrial microsatellite instability in colorectal carcino-mas-frequency and association with nuclear microsatellite instability. Cancer Lett 2005; 219:97-103.
171. Xu L, Hu Y, Chen B, et al. Mitochondrial polymorphisms as risk factors for endometrial cancer in southwest China. Int J Gynecol Cancer 2006; 16:1661-1667.
172. Liu VW, Yang HJ, Wang Y, et al. High frequency of mitochondrial genome instability in human endometrial carcinomas. Br J Cancer 2003; 89:697-701.
173. Wang Y, Xue WC, Liu VW, Ngan HY. Detection of mosaic pattern of mitochondrial DNA alterations in different populations of cells from the same endometrial tumor. Mitochondrion 2007; 7:171-175.
174. Kumimoto H, Yamane Y, Nishimoto Y, et al. Frequent somatic mutations of mitochondrial DNA in esophageal squamous cell carcinoma. Int J Cancer 2004; 108:228-231.
175. Abnet CC, Huppi K, Carrera A, et al. Control region mutations and the 'common deletion' are frequent in the mitochondrial DNA of patients with esophageal squamous cell carcinoma. BMC Cancer 2004; 4:30.
176. Lievre A, Blons H, Houllier AM, et al. Clinicopathological signifcance of mitochondrial D-Loop mutations in head and neck carcinoma. Br J Cancer 2006; 94:692-697.
177. Lee HC, Yin PH, Lin JC, et al. Mitochondrial genome instability and mtDNA depletion in human cancers. Ann N Y Acad Sci 2005; 1042:109-122.
178. Wu CW, Yin PH, Hung WY, et al. Mitochondrial DNA mutations and mitochondrial DNA depletion in gastric cancer. Genes Chromosomes Cancer 2005; 44:19-28.
179. Lee HC, Hsu LS, Yin PH, Lee LM, Chi CW. Heteroplasmic mutation of mitochondrial DNA D-loop and 4977-bp deletion in human cancer cells during mitochondrial DNA depletion. Mitochondrion 2007; 7:157-163.
180. Tamori A, Nishiguchi S, Nishikawa M, et al. Correlation between clinical characteristics and mitochondrial D-loop DNA mutations in hepatocellular carcinoma. J Gastroenterol 2004; 39:1063-1068.
181. Yoneyama H, Hara T, Kato Y, et al. Nucleotide sequence variation is frequent in the mitochondrial DNA displacement loop region of individual human tumor cells. Mol Cancer Res 2005; 3:14-20.
182. Kurtz A, Lueth M, Kluwe L, et al. Somatic mitochondrial DNA mutations in neurofibromatosis type 1-associated tumors. Mol Cancer Res 2004; 2:433-441.
183. Suzuki M, Toyooka S, Miyajima K, et al. Alterations in the mitochondrial displacement loop in lung cancers. Clin Cancer Res 2003; 9:5636-5641.
184. Pai CY, Hsieh LL, Lee TC, et al. Mitochondrial DNA sequence alterations observed between blood and buccal cells within the same individuals having betel quid (BQ)-chewing habit. Forensic Sci Int 2006; 156:124-130.
185. Maki J, Robinson K, Reguly B, et al. Mitochondrial genome deletion aids in the identifcation of false- and true-negative prostate needle core biopsy specimens. Am J Clin Pathol 2008; 129:57-66.
186. Chen JZ, Gokden N, Greene GF, Mukunyadzi P, Kadlubar FF. Extensive somatic mitochondrial mutations in primary prostate cancer using laser capture microdissection. Cancer Res 2002; 62:6470-6474.
187. Chen JZ, Kadlubar FF. Mitochondrial mutagenesis and oxidative stress in human prostate cancer. J Environ Sci Health C Environ Carcinog Ecotoxicol Rev 2004; 22:1-12.
188. Lohrer HD, Hieber L, Zitzelsberger H. Differential mutation frequency in mitochondrial DNA from thyroid tumours. Carcinogenesis 2002; 23:1577-1582.
189. Van Trappen PO, Cullup T, Troke R, et al. Somatic mitochon-drial DNA mutations in primary and metastatic ovarian cancer. Gynecol Oncol 2007; 104:129-133.
190. Kose K, Hiyama T, Tanaka S, et al. Nuclear and mitochondrial DNA microsatellite instability in gastrointestinal stromal tumors. Pathobiology 2006; 73:93-97.
191. Nishikawa M, Nishiguchi S, Shiomi S, et al. Somatic muta- tion of mitochondrial DNA in cancerous and noncancerous liver tissue in individuals with hepatocellular carcinoma. Cancer Res 2001; 61:1843-1845.
192. Lee HC, Li SH, Lin JC, et al. Somatic mutations in the D-loop and decrease in the copy number of mitochondrial DNA in human hepatocellular carcinoma. Mutat Res 2004; 547:71-78.
193. Tamura G, Nishizuka S, Maesawa C, et al. Mutations in mito-chondrial control region DNA in gastric tumours of Japanese patients. Eur J Cancer 1999; 35:316-319.
194. Montanini L, Regna-Gladin C, Eoli M, et al. Instability of mitochondrial DNA and MRI and clinical correlations in malignant gliomas. J Neurooncol 2005; 74:87-89.
195. Kirches E, Krause G, Weis S, Mawrin C, Dietzmann K. Comparison between mitochondrial DNA sequences in low grade astrocytomas and corresponding blood samples. Mol Pathol 2002; 55:204-206.
196. Miyazono F, Schneider PM, Metzger R, et al. Mutations in the mitochondrial DNA D-Loop region occur frequently in adenocarcinoma in Barrett's esophagus. Oncogene 2002; 21:3780-3783.
197. Guo XG, Guo QN. Mutations in the mitochondrial DNA D- Loop region occur frequently in human osteosarcoma. Cancer Lett 2006; 239:151-155.
198. Wardell TM, Ferguson E, Chinnery PF, et al. Changes in the human mitochondrial genome after treatment of malignant disease. Mutat Res 2003; 525:19-27.
199. Tang M, Baez S, Pruyas M, et al. Mitochondrial DNA mutation at the D310 (displacement loop) mononucleotide sequence in the pathogenesis of gallbladder carcinoma. Clin Cancer Res 2004; 10:1041-1046.
200. El Meziane A, Lehtinen SK, Holt IJ, Jacobs HT. Mitochon-drial tRNALeu isoforms in lung carcinoma cybrid cells containing the np 3243 mtDNA mutation. Hum Mol Genet 1998; 7:2141-2147.
201. Sangkhathat S, Kusafuka T, Yoneda A, et al. Renal cell carcinoma in a pediatric patient with an inherited mitochondrial mutation. Pediatr Surg Int 2005; 21:745-748.
202. Lombes A, Bories D, Girodon E, et al. The frst pathogenic mitochondrial methionine tRNA point mutation is discovered in splenic lymphoma. Hum Mutat 1998; Suppl 1:S175-S183.
203. Han CB, Xin Y, Yang XF, et al. [Mutation of mitochondrial 12S rRNA in gastric carcinomas and its signifcance]. Zhonghua Zhong Liu Za Zhi 2005; 27:260-264.